EyePoint Announces Participation at Upcoming Investor Conferences

Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT), a company focused on developing therapeutics for serious retinal diseases, has announced its participation in three upcoming investor conferences in June 2025:

• Jefferies Global Healthcare Conference on June 4 at 1:25 p.m. ET
• Goldman Sachs 46th Annual Global Healthcare Conference on June 10 at 2:40 p.m. ET
• Guggenheim BioFrontier Boston Event on June 25 at 4:00 p.m. ET

The company will participate in fireside chats at each event, with live webcasts and archived replays available through EyePoint's investor relations website.

WATERTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate in fireside chats at the following upcoming investor conferences:

• Jefferies Global Healthcare Conference
  Date: Wednesday, June 4, 2025
  Time: 1:25 p.m. ET

• Goldman Sachs 46^th Annual Global Healthcare Conference
  Date: Tuesday, June 10, 2025
  Time: 2:40 p.m. ET

• Guggenheim BioFrontier Boston Event
  Date: Wednesday, June 25, 2025
  Time: 4:00 p.m. ET

A live webcast and subsequent archived replay of each fireside chat may be accessed via the Investors section of the Company website at www.eyepointpharma.com.

About EyePoint

EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™ is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E^™. Supported by robust safety and efficacy data to date, DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration, the leading cause of vision loss among people 50 years of age and older in the United States and recently completed a Phase 2 clinical trial in diabetic macular edema.

The proven Durasert^® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products in multiple disease indications. EyePoint is headquartered in Watertown, Massachusetts, and operates a commercial-scale manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU^™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product candidate; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors:

Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com

Media Contact:

Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

FAQ

What investor conferences will EyePoint Pharmaceuticals (EYPT) attend in June 2025?

EyePoint will participate in three conferences: Jefferies Global Healthcare Conference (June 4), Goldman Sachs Global Healthcare Conference (June 10), and Guggenheim BioFrontier Boston Event (June 25).

How can investors access EyePoint Pharmaceuticals' (EYPT) conference presentations?

Investors can access live webcasts and archived replays of the fireside chats through the Investors section of EyePoint's website at www.eyepointpharma.com.

What is EyePoint Pharmaceuticals' (EYPT) main business focus?

EyePoint Pharmaceuticals focuses on developing and commercializing innovative therapeutics for patients with serious retinal diseases.

What time is EyePoint's (EYPT) presentation at the Goldman Sachs Healthcare Conference 2025?

EyePoint will present at the Goldman Sachs Healthcare Conference on Tuesday, June 10, 2025, at 2:40 p.m. ET.